Kornimate/medical-research-clean huggingface dataset:
fetuin-a phosphorylation status in insulin resistance and metabolic syndrome

Conditions: Obesity; Metabolic Syndrome

Summary: fetuin-a has been identified as a novel physiological regulator of insulin action in vitro, in intact cells and in vivo in animals. previous research has shown that circulating levels of fetuin-a were increased in animal models of insulin resistance and diabetes. additionally, several human investigation studies demonstrate a correlation of fetuin-a levels with body mass index, insulin resistance, and a fatty liver. recently, the investigators have elucidated the role of fetuin-a phosphorylation in the regulation of insulin action, demonstrating that phosphorylation is critical for the inhibitory activity of fetuin-a. the objectives of this study are twofold: (1) quantitate phosphorylated fetuin-a levels in individuals with insulin resistance and metabolic syndrome, and (2) investigate the effects of lifestyle modifications (acute or chronic exercise and dietary modifications) on fetuin-a phosphorylation and insulin sensitivity.

there are several objectives of this study: (1) quantitate phosphorylated fetuin-a levels and the daily variation in these levels in individuals with insulin resistance and metabolic syndrome; (2) investigate the short-term responses of fetuin-a phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise; (3) characterize and compare the total and temporal changes in fetuin-a phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification, and; (4) investigate the influence of weight loss on the short-term responses of fetuin-a phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise. our hypothesis is that phosphofetuin-a levels are tightly correlated with insulin resistance and that lifestyle modifications will improve insulin sensitivity and decrease phosphorylated fetuin-a levels.

Eligibility criteria:
inclusion criteria: * 30 to 65 years of age * obese (bmi \> 30 kg⋅m2 or % fat \> 30, and waist girth \> 88 cm) * weight stable over the previous 6 months exclusion criteria: * smoker * documented cardiovascular or metabolic disease * currently taking medication to alter lipid or glucose metabolism * practicing regular leisure physical activity over the previous 6 months * engaged in strenuous vocational activity over the previous 6 months * signs or symptoms of latent heart disease * conditions that would preclude treadmill walking
comparison of pain therapeutic effects after benign mastectomy

Conditions: Pain, Postoperative; Mastectomy

Summary: with the incremental trend of benign breast tumor, the surgical process of mastectomy was proceeded too much every day, especially in the maternal health care hospital, but whether the investigators can find another way to relieve the postoperative pain after such an operation is still unknown. the investigators hypothesized that the pain from the relatively small surgery may not be significant compared to different treatments, even if no drug was delivered to them. the investigators are enrolling patients who underwent mastectomy from benign breast tumor, and are observing the analgesic effects of different drugs.


Eligibility criteria:
inclusion criteria: * chinese * no cardiac and pulmonary diseases * asa i-ii * no alcohol drinking. exclusion criteria: * \ 65yrs * history of central active drugs administration * drug abuse * hypertension * diabetes * any other chronic diseases.

Keywords: breast neoplasms non-steroidal anti-inflammatory agents analgesia
safety & efficacy study of quetiapine fumarate (seroquel®) vs. placebo & active control in generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this study is to demonstrate that quetiapine sr (seroquel®) is efficacious and safe in the acute treatment of patients with generalized anxiety disorder. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * patient has a documented clinical diagnosis of generalized anxiety disorder. * be able to understand and comply with the requirements of the study. * able to understand and provide written informed consent exclusion criteria: * patients (female) must not be pregnant or lactating * current or past diagnosis of stroke or transient ischemic attack (tia).

Keywords: gad anxiety
evaluation of nanodropper-mediated microdrops vs. standard drops of 0.5% timolol maleate in glaucoma patients

Conditions: Glaucoma; Glaucoma, Open-Angle; Glaucoma, Primary Open Angle; Glaucoma and Ocular Hypertension; Ocular Hypertension

Summary: the purpose of this study is to evaluate the effect of microdrops vs. standard eyedrops of 0.5% timolol maleate in adults with primary open-angle glaucoma or ocular hypertension in terms of intraocular pressure-lowering efficacy and cardiovascular side effects.

this randomized, single-masked, parallel study aims to evaluate the safety and efficacy of microdrops of 0.5% timolol maleate administered with nanodropper (experimental intervention) compared to standard drops of 0.5% timolol maleate (active comparator) in patients with primary open-angle glaucoma (oag) or ocular hypertension (oht) at aravind eye hospital. at the beginning of the test day, baseline (pre-drug) intraocular pressure (iop), resting heart rate (hr), and resting systolic and diastolic blood pressure (bp) measurements will be collected. participants will be randomized to receive standard eyedrops or microdrops of 0.5% timolol maleate (one drop per eye), which will be administered by a trained technician at t = 0. iop, hr, and bp measurements will be repeated by a masked investigator at t = 1, 2, 5, and 8 hours after drug administration.

Eligibility criteria:
inclusion criteria: * ≥18 years old * recent diagnosis of primary oag or oht * treatment-naive (not currently using ophthalmic medication) * baseline iop between 21-35 mm hg * corrected snellen visual acuity of 6/60 or better in each eye exclusion criteria: * \<18 years old * a recent history (within the past 6 months) of ocular trauma, infection, or uveitis * baseline iop \ 35 mm hg * history of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease * history of borderline or uncontrolled systemic arterial hypertension * use of any systemic α-agonist or β-blocker within 30 days of study commencement * history of receiving general anesthesia within the previous 30 days * pregnant women and nursing mothers

Keywords: glaucoma eyedrops microdrops
safety study of subcutaneous ig nextgen 16% in patients with primary immunodeficiency

Conditions: Primary Immune Deficiency

Summary: the study aims to assess the safety and tolerability of subcutaneous ig nextgen 16% in patients with primary immune deficiency who require immunoglobulin (ig) g replacement therapy. ig nextgen 16% is a liquid immunoglobulin (antibody) preparation.

this is a phase 3, open label, multi-centre, study for patients requiring ig replacement therapy. this study is a follow-on study to patients who have completed the cslct-scig-05-23 clinical trial and wish to continue subcutaneous treatment with ig nextgen 16% . additionally, patients currently receiving ivig with unacceptable adverse reactions or unable to tolerate ivig as well as patients receiving alternate ig products via the sc route may be enrolled in this study. patients must not be eligible for any of the sponsor's ongoing pid studies that are still open to enrolment.

Eligibility criteria:
inclusion criteria: 1. age \>3 years of age. 2. pid patients receiving ig replacement therapy. 3. patients must have completed or withdrawn from cslct-scig-05-23 and wish to continue scig therapy; or, patients ineligible for cslct-scig-05-23 but for whom the investigator believes scig may be a suitable form of ig replacement, for reasons such as: poor tolerability of ivig, difficult venous access, or, preferred route of administration. 4. patient is capable of self-administering ig nextgen 16% exclusion criteria: 1. patients eligible for cslct-scig-05-23 if still open for recruitment. 2. patients with known anaphylaxis reactions to immunoglobulin therapy. 3. patients with known selective iga deficiency or antibodies to iga with a history of reactions to ig therapy. 4. patients with protein-losing enteropathies. 5. patients who are suffering from an acute or chronic medical condition, other than pid, which may, in the opinion of the investigator, affect their treatment or the conduct of the trial. 6. females who are pregnant, breast feeding or planning a pregnancy during the course of the study. females who are of child bearing potential must have a negative pregnancy test at screening. 7. patients unwilling to comply with the protocol.

Keywords: primary immune deficiency subcutaneous immunoglobulin g
kefir and metabolic syndrome

Conditions: Metabolic Syndrome; Obesity; Hypertension; Hyperlipidemias; Insulin Resistance

Summary: metabolic syndrome is a cluster of metabolic disorders which increases the risk for diabetes and cardiovascular disease. in recent years, research has shown that probiotics may have positive effects on metabolic syndrome components. although several health-promoting effects of kefir, have been suggested, there is limited evidence for its potential effect on metabolic syndrome. therefore, it is necessary to clarify the effects of kefir on metabolic disorders including obesity, dyslipidemia, diabetes, and hypertension. to address the research gap, this study aimed to investigate the effects of daily kefir consumption on metabolic syndrome components, inflammatory response and gut microbiota composition in adults with mets. the study was planned as a randomized, controlled, parallel design and completed with a total of 62 individuals who were diagnosed with metabolic syndrome according to the international diabetes federation (idf) criteria. participants were randomized into two groups and received daily 180 ml of kefir (n=31) or milk (as control) (n=31) for 12 weeks. participants were assessed at baseline, week 4, week 8, and week 12 and at all controls dietary records, anthropometric measurements, and blood samples were collected. at baseline and 12th-week fecal samples were also collected in order to analyze gut microbiota composition.


Eligibility criteria:
inclusion criteria: * 18-65 years old subjects * subjects diagnosed with metabolic syndrome according to the international diabetes federation (idf) criteria. exclusion criteria: * existence of lactose intolerance * existence of type 1 diabetes * existence of abnormal thyroid hormone levels * existence of chronic gastrointestinal system disease * existence of cancer * existence of severe liver disease * existence of kidney insufficiency * existence of immunodeficiency * taking medication to regulate blood glucose (except metformin) or lipid levels * taking antibiotics prior to one month of the study * consuming regular probiotic food or supplement * taking supplement which may affect the metabolic outcomes such as prebiotic or omega-3 * dieting for weight loss or for another disease * being pregnant and breastfeeding.

Keywords: probiotics dairy products kefir gut microbiota
addressing medium- to long-term ebola associated psychological distress and psychosocial problems in central uganda

Conditions: Ebola Virus Disease

Summary: screen participants attending 11 healthcare facilities in mubende district for psychological distress using the locally validated luganda or english version of the who- self report questionnaire (srq-20). those individuals found to have significant psychological distress (a score of 6 and above) will be offered ebola+d intervention \[a stepped care collaborative delivery model to address the medium- to long-term ebola associated psychological distress and psychosocial problems\] . a cohort of ebola virus disease (evd) affected individuals accessing the ebola +d mental health intervention will be recruited and followed up for 12 months with assessments at three time points; baseline, 3 months and 12 months.

ebola virus disease (evd) is associated with high mortality, physical morbidity among patients and survivors, plus being associated with significant mental health and psychosocial problems among patients/survivors, their family members, members of the affected communities, health workers and volunteers. to support the medical services of mubende district cope with the ebola associated mental health and psychosocial problems, the ministry of health of uganda has partnered with the mrc/uvri \& lshtm uganda research unit to implement a health systems strengthening project in the district entitled, 'addressing the medium to long-term ebola associated psychological distress and psychosocial problems in mubende district in central uganda (ebola+d project)'. methodology: the project will be undertaken in the 11 selected health care facilities in mubende district. members of the community attending these selected health care facilities will be screened for psychological distress using the locally validated luganda or english version of the who- self report questionnaire (srq-20). those individuals found to have significant psychological distress (a score of 6 and above) will be offered ebola+d intervention. a cohort of evd affected individuals accessing the ebola +d mental health intervention will be recruited and followed up for 12 months with assessments at three time points; baseline, 3 months and 12 months.

Eligibility criteria:
inclusion criteria: * community member of mubende district staying within the catchment area of the primary health care facility (phcf); * 18years and above, * able to communicate in either english or luganda (local language spoken in the study region and the language into which the questionnaires will be translated), * has a who srq-20 score of 6 and above (except for ebola survivors who are eligible even when their srq-20 score is either below or above 6). - exclusion criteria: * unable to engage with the research process for any reason that may include sensory impairment or cognitive impairment

Keywords: ebola associated psychological distress
children's mercy teens with type 1 diabetes will participate in an online peer support group.

Conditions: Type 1 Diabetes

Summary: the goal of this observational study is to examine the impact of an online peer support group in children's mercy teens with type 1 diabetes. the main objectives are to examine the feasibility and acceptability of the diabetes link's online social platform discord among youth with diabetes as it relates to peer support, diabetes management, and usability and to examine the efficacy/magnitude of the effect of the discord group on treatment adherence among youth with diabetes. participants will participate in an online peer support group for 3 months and provide their feedback while doing so.


Eligibility criteria:
inclusion criteria: * t1d diagnosis * 16-19 years old * 11th-12th graders * access to smartphone/laptop * english-speaking
mucinex® for treatment of filamentary keratitis

Conditions: Filamentary Keratitis

Summary: it is a pilot study aimed to determine if oral mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

the study is aimed to determine if oral administration of mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. subjects will be instructed to take 600 mg tablets of extended release mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Eligibility criteria:
inclusion criteria: * patients with filamentary keratitis * 18 years and older exclusion criteria: * active ocular surface infection of any type * recent ocular surgery (\<30 days) history of nephrolithiasis as mucinex® has been associated in rare cases of development of kidney stones * schirmer's test\<3mm * history of hypersensitivity to mucinex® * concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.
cross-validation of a predictive model of response to anti-tnf alpha based on oxylipin response in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-tnf alpha treatment . the main questions it aims to answer is: is the predictive model created using oxylipins effective? participants starting anti-tnf alpha treatment will have a blood sample taken before starting treatment and 6 months afterwards.


Eligibility criteria:
inclusion criteria: * male or female patient aged 18 years or older with rheumatoid arthritis according to acr eular 2010 criteria * active disease as defined by das-28-crp\>3.2 * naive to targeted biologic or synthetic therapy * rheumatologist's decision to start anti-tnfα treatment * stable corticosteroid therapy ≤ 10 mg/day * patient enrolled in or benefiting from a social security scheme * patient who has given written informed consent to participate in the study exclusion criteria: * contraindication to biological treatment (cancer or history of cancer) * treatment with non-steroidal anti-inflammatory drugs in the 2 weeks prior to enrolment * protected persons (pregnant and/or breastfeeding women, persons under guardianship or conservatorship)

Keywords: rheumatoid, arthritis oxylipin cytokin eular response polyunsaturated fat
extension study evaluating etanercept in ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ascend (0881a3-402)(nct00247962) study.


Eligibility criteria:
inclusion criteria: * patients who completed 16 weeks of treatment and have completed the baseline health care resource utilization questionnaire at screening in the ascend study 0881a3-402-ww from participating countries. exclusion criteria: * withdrawal from the ascend study for safety or any other reason.
efficacy of hypnosis in anxiety/pain reduction in children during pulpotomies

Conditions: Dental Anxiety; Pain

Summary: anxiety and pain are emotions that the child often experiences in the dental office, generating the appearance of negative, uncooperative and even disruptive behaviors during the treatment; these make it difficult for dental care and the possibility of establishing a relationship of trust between the pediatric dentist and the patient. the pediatric dentist must promote a positive attitude of the child throughout the dental treatment, keep the child calm and avoid feeling pain is essential at each appointment. when carrying out dental treatments that are more invasive or painful for the patient, such as pulpotomies, it is difficult to distinguish and separate anxiety from pain. in this project, anxiety/pain will be managed as a whole, to assess it with the same scale, and to correlate the scores obtained with the variations in skin conductance and heart rate, before, during and after perform pulpotomies in children.


Eligibility criteria:
inclusion criteria: * without previous dental experiences, patients with clinical and radiographic indication of pulpotomy in at least one temporary inferior molar, clinically healthy patients, patients whose parents accept entry into the study and who sign the informed consent. exclusion criteria: * patients who have received hypnosis before.

Keywords: dental anxiety pain child pediatric dentistry hypnosis
study of ontak in patients with b-cell chronic lymphocytic leukemia (cll)

Conditions: Leukemia, Lymphocytic, Chronic

Summary: the purpose of this study is to evaluate the safety and effectiveness of ontak in previously treated patients with chronic lymphocytic leukemia (cll)


Eligibility criteria:
inclusion criteria: * patients with b-cell chronic lymphocytic leukemia, rai stage 0-ii with indication for treatment by nci working group criteria or rai stage iii or iv. * patients must have received at least one prior purine analogue-based chemotherapy regimen. * ecog performance status of 0, 1, or 2. * female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends. exclusion criteria: * prior treatment with ontak (dab389il-2) or dab486il-2. * received any therapy for cll within 35 days prior to study entry.
enhanced recovery after surgery (eras) total knee replacement (tkr) with a transitional pain service

Conditions: Anesthesia

Summary: a comparison of two anesthetic techniques for total knee replacements: (1) peri-articular injection (pai), local infiltration between the popliteal artery and capsule of the knee block (ipack) and single-shot adductor canal block (acb) vs. (2) pai, ipack and continuous adductor canal block catheter (acc).

patients will be randomized to one of two groups: one group will receive a pai, ipack and single-shot adductor canal block; one group will receive pai, ipack and continuous adductor canal block catheter.

Eligibility criteria:
inclusion criteria: * patients with osteoarthritis scheduled for a primary total knee arthroplasty with a participating surgeon * planned use of regional anesthesia * ability to follow study protocol * english speaking (secondary outcomes include questionnaires validated in english only) * lives within one hour of the hospital * has a smart phone exclusion criteria: * hepatic or renal insufficiency * younger than 18 years old or older than 65 years ol * patients undergoing general anesthesia * allergy or intolerance to one of the study medications * bmi \>40 * diabetes * american society of anesthesiologists (asa) status iii or iv * chronic gabapentin/pregabalin use (regular use for longer than 3 months) * patients with chronic pain (from a referral to chronic pain service) or a pain catastrophizing scale (pcs \>30) * patients with severe valgus deformity or flexion contracture * patients unable to follow home catheter instructions and unwilling to go home with an infusing catheter * patients who have no home caregivers in the event that a catheter is to be sent home with the patient * patients with planned stay at rehab facility (to avoid medical device being tampered with at the rehab facility) * non-english speakers (secondary outcomes include questionnaires validated in english only)